CUE

Company Overview — What Does Cue Biopharma, Inc. Do?

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cue Biopharma, Inc. (CUE) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Daniel R. Passeri and employs approximately 60 people. With a market capitalization of $20M, CUE is one of the notable companies in the Healthcare sector.

Cue Biopharma, Inc. (CUE) Stock Rating — Avoid (April 2026)

As of April 2026, Cue Biopharma, Inc. receives a Avoid rating with a composite score of 19.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CUE ranks #4,360 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cue Biopharma, Inc. ranks #805 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CUE Stock Price and 52-Week Range

Cue Biopharma, Inc. (CUE) currently trades at $0.43. The stock gained $0.14 (46.8%) in the most recent trading session. The 52-week high for CUE is $1.05, which means the stock is currently trading -59.0% from its annual peak. The 52-week low is $0.23, putting the stock 86.8% above its annual trough. Recent trading volume was 232.3M shares, indicating strong institutional interest and high liquidity.

Is CUE Overvalued or Undervalued? — Valuation Analysis

Cue Biopharma, Inc. (CUE) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.70x, versus the sector average of 2.75x. The price-to-sales ratio is 2.07x, compared to 1.66x for the average Healthcare stock.

At current multiples, Cue Biopharma, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cue Biopharma, Inc. Profitability — ROE, Margins, and Quality Score

Cue Biopharma, Inc. (CUE) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -139.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -87.3% versus the sector average of -33.1%.

On a margin basis, Cue Biopharma, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -957.8% (sector: -66.1%). Net profit margin stands at -951.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -19.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CUE Debt, Balance Sheet, and Financial Health

Cue Biopharma, Inc. has a debt-to-equity ratio of 60.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.74x, indicating strong short-term liquidity. Total debt on the balance sheet is $2M. Cash and equivalents stand at $12M.

CUE has a beta of 1.23, meaning it is more volatile than the broader market — a $10,000 investment in CUE would be expected to move 22.5% more than the S&P 500 on any given day. The stability factor score for Cue Biopharma, Inc. is 23/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cue Biopharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cue Biopharma, Inc. reported revenue of $9M and earnings per share (EPS) of $-0.28. Net income for the quarter was $-37M. Gross margin was 100.0%. Operating income came in at $-37M.

In FY 2025, Cue Biopharma, Inc. reported revenue of $27M and earnings per share (EPS) of $-0.28. Net income for the quarter was $-27M. Revenue grew 195.7% year-over-year compared to FY 2024. Operating income came in at $-27M.

In Q3 2025, Cue Biopharma, Inc. reported revenue of $2M and earnings per share (EPS) of $-0.07. Net income for the quarter was $-7M. Revenue grew -35.6% year-over-year compared to Q3 2024. Operating income came in at $-8M.

In Q2 2025, Cue Biopharma, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.09. Net income for the quarter was $-8M. Revenue grew 11.1% year-over-year compared to Q2 2024. Operating income came in at $-9M.

Over the past 8 quarters, Cue Biopharma, Inc. has demonstrated a growth trajectory, with revenue expanding from $3M to $9M. Investors analyzing CUE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CUE Dividend Yield and Income Analysis

Cue Biopharma, Inc. (CUE) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CUE Momentum and Technical Analysis Profile

Cue Biopharma, Inc. (CUE) has a momentum factor score of 9/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 37/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 53/100 reflects moderate short selling activity.

CUE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cue Biopharma, Inc. (CUE) ranks #805 out of 838 stocks based on the Blank Capital composite score. This places CUE in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CUE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CUE vs S&P 500 (SPY) comparison to assess how Cue Biopharma, Inc. stacks up against the broader market across all factor dimensions.

CUE Next Earnings Date

No upcoming earnings date has been announced for Cue Biopharma, Inc. (CUE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CUE? — Investment Thesis Summary

The quantitative profile for Cue Biopharma, Inc. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. Momentum is weak at 9/100, a headwind for near-term performance. High volatility (stability score 23/100) increases portfolio risk.

In summary, Cue Biopharma, Inc. (CUE) earns a Avoid rating with a composite score of 19.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CUE stock.

Related Resources for CUE Investors

Explore more research and tools: CUE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CUE head-to-head with peers: CUE vs AZN, CUE vs SLGL, CUE vs VMD.